“The minimum inhibiting concentrations (MIC) of delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) for staphylococci and streptococci in broth are in the range of 1-5 mug/ml.
In the same range, both compounds are also bactericidal.
In media containing 4% serum or 5% blood the antibacterial activity is strongly reduced (MIC 50 mug/ml). Gram-negative bacteria are resistant to THC and CBD.”
“The systemic inflammatory response syndrome can be self-limited or can progress to severe sepsis and septic shock. Despite significant advances in the understanding of the molecular and cellular mechanisms of septic shock, it is still one of the most frequent and serious problems confronting clinicians in the treatments. And the effects of cannabinoid receptor 2 (CB2R) on the sepsis still remain undefined.
The present study was aimed to explore the role and mechanism of CB2R in acute sepsis model of mice. Here, we found that mice were more vulnerable for lipopolysaccharide- (LPS-) induced death and inflammation after CB2R deletion (CB2R(-/-)). CB2R agonist, GW405833, could significantly extend the survival rate and decrease serum proinflammatory cytokines in LPS-treated mice. GW405833 dose-dependently inhibits proinflammatory cytokines release in splenocytes and peritoneal macrophages as well as splenocytes proliferation, and these effects were partly abolished in CB2R(-/-) splenocytes but completely abolished in CB2R(-/-) peritoneal macrophages. Further studies showed that GW405833 inhibits LPS-induced phosphorylation of ERK1/2 and STAT3 and blocks I κ B α degradation and NF- κ B p65 nuclear translocation in macrophages.
All data together showed that CB2R provides a protection and is a potential therapeutic target for the sepsis.”
Human peripheral cannabinoid receptor CB2, a G protein-coupled receptor (GPCR) involved in regulation of immune response has become an important target for pharmaceutical drug development.
Structural and functional studies on CB2 may benefit from immobilization of the purified and functional receptor onto a suitable surface at a controlled density and, preferably in a uniform orientation. The goal of this project was to develop a generic strategy for preparation of functional recombinant CB2 and immobilization at solid interfaces. Expression of CB2 as a fusion with Rho-tag (peptide composed of the last nine amino acids of rhodopsin) in E. coli was evaluated in terms of protein levels, accessibility of the tag, and activity of the receptor. The structural integrity of CB2 was tested by ligand binding to the receptor solubilized in detergent micelles, captured on tag-specific monoclonal 1D4 antibody-coated resin. Highly pure and functional CB2 was obtained by sequential chromatography on a 1D4- and Ni-NTA- resin and its affinity to the 1D4 antibody characterized by surface plasmon resonance (SPR). Either the purified receptor or fusion CB2 from the crude cell extract was captured onto a 1D4 -coated CM4 chip (Biacore) in a quantitative fashion at uniform orientation as demonstrated by the SPR signal. Furthermore, the accessibility of the extracellular surface of immobilized CB2 and the affinity of interaction with a novel monoclonal antibody NAA-1 was studied by SPR.
In summary, we present an integral strategy for purification, surface immobilization, ligand- and antibody binding studies of functional cannabinoid receptor CB2.”
“Potential treatments for Alzheimer’s disease, cancer and many other illnesses are being blocked by anti-drug laws, according to a new editorial review published in Nature Reviews Neuroscience.”
“Smoking cannabis appeared to reduce tremor and pain and improve sleep among Parkinson’s disease patients, researchers from Israel reported here.
Overall, patients’ scores on the standard Unified Parkinson’s Disease Rating Scale (UPDRS) averaged 33 before they smoked cannabis in the laboratory and averaged 24 after 30 minutes (P<0.01), Ruth Djaldetti, MD, of Tel Aviv University Israel, reported at her poster presentation at the International Congress on Parkinson’s Disease and Movement Disorders.
“We not only saw improvement in tremor in these patients, but also in rigidity and in bradykinesia,” Djaldetti told MedPage Today. “I would recommend use of marijuana to my patients as a last resort if nothing else was working for them or if they had pain.””
“…Scientists were therefore surprised to learn that a study of more than 2,000 people found no increase in the risk of developing lung cancer for marijuana smokers.
“We expected that we would find that a history of heavy marijuana use–more than 500 to 1,000 uses–would increase the risk of cancer from several years to decades after exposure to marijuana,” explains physician Donald Tashkin of the University of California, Los Angeles, and lead researcher on the project. But looking at residents of Los Angeles County, the scientists found that even those who smoked more than 20,000 joints in their life did not have an increased risk of lung cancer.
The study does not reveal how marijuana avoids causing cancer. Tashkin speculates that perhaps the THC chemical in marijuana smoke prompts aging cells to die before becoming cancerous. Tashkin and his colleagues presented the findings yesterday at a meeting of the American Thoracic Society in San Diego.”
More: http://www.scientificamerican.com/article.cfm?id=large-study-finds-no-link
| “Donald Tashkin’s is a tale cannabis pushers like to repeat. The physician and professor at UCLA’s David Geffen School of Medicine set out to prove — via a study funded by the National Institutes on Drug Abuse — that marijuana is bad for you. Instead, a long-term study found no solid link between marijuana use and lung cancer, in sharp contrast to tobacco terrible effects on health.”
|
| “Similar findings were repeated all over the world. In a collection and review of studies on marijuana’s effect on the lungs, published in the June issue of the Annals of the American Thoracic Society, Tashkin concludes that compared to tobacco smoking, heavy marijuana use has “relatively small and far lower” risks.
This despite an average joint marijuana having four times the tar of a typical American Spirit. How can this be? It’s worth remembering that this is not a new development — Tashkin’s long-term study was published in 2006. And well before that — as in the 19th Century, when cannabis tinctures and other marijuana medicines were sold in pharmacies — doctors were prescribing marijuana as a treatment for asthma patients.” |
“Donald Tashkin‘s is a tale cannabis pushers like to repeat. The physician and professor at UCLA‘s David Geffen School of Medicine set out to prove — via a study funded by the National Institutes on Drug Abuse — that marijuana is bad for you. Instead, a long-term study found no solid link between marijuana use and lung cancer.
Similar findings were repeated all over the world. In a review of studies on marijuana’s effect on the lungs, published in the June issue of the Annals of the American Thoracic Society, Tashkin concludes that compared to tobacco smoking, heavy marijuana use has “relatively small and far lower” risks.”
More: http://www.sfweekly.com/2013-06-19/news/ucla-medical-marijuana-cancer/full/
“Cannabinoids show promise for the treatment of various medical conditions such as emesis, anorexia, pain, cancer, multiple sclerosis, Parkinson’s disease and glaucoma.
The objective of the present work was to assess the feasibility of developing cannabinoid loaded poly-ε-caprolactone (PCL) microparticles prepared by the oil-in-water emulsion-solvent evaporation technique as a suitable dosage form for their administration.
In vitro cell viability studies demonstrated the antitumoral activity of CBD released from microparticles. After 4 and 7 days of incubation, CBD in microspheres significantly inhibited the growth of MDA-MB-231 cells by 60% as compared to the 50% attained with free drug.
The results suggest that PCL microparticles could be an alternative delivery system for long-term cannabinoid administration, showing potential therapeutic advantages over free drug.”
“Cannabinoids present an interesting therapeutic potential as antiemetics, appetite stimulants in debilitating diseases (cancer, AIDS and multiple sclerosis), analgesics, and in the treatment of multiple sclerosis and cancer, among other conditions.
However, despite their high clinical potential, only few dosage forms are available to date. In this paper, the development of Δ9-tetrahydrocannabinol (THC) biodegradable microspheres as an alternative delivery system for cannabinoid parenteral administration is proposed. Tetrahydrocannabinol was encapsulated into biodegradable microspheres by the oil-in-water (o/w) emulsion solvent evaporation method. Several formulations were prepared using different drug:polymer ratios. The influence of antioxidant (α-tocopherol acetate) concentration on the release of THC from the microparticles was studied. Elevated process yield and entrapment efficiencies were achieved.The in vitro drug release studies showed that the encapsulated drug was released over a two week period.
As THC has shown therapeutic potential as anticancer drug, the efficacy of the microspheres was tested on different cancer cell lines.
Interestingly, the microspheres were able to inhibit cancer cell proliferation during the nine-day study period.
All the above results suggest that the use of biodegradable microspheres would be a suitable alternative delivery system for THC administration.”
